Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in adult ADHD impulsivity
NCT05278104Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Atomoxetine with Placebo (2 arms). Primary endpoints: Barratt Impulsiveness Questionnaire v.11 Total at 14 days and Short Urgency, Perseverance, Premeditation, and Sensation Seeking-Positive Urgency Impulsive Behavior Scale Total at 14 days. Started Sep 2023; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05278104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278104.